Milder chemo shows promise for HER2+ breast cancer patients
NCT ID NCT07421141
First seen Feb 21, 2026 · Last updated Jun 14, 2026 · Updated 19 times
Summary
This study tests whether a less intense chemotherapy combination (paclitaxel, trastuzumab, pertuzumab) can work as well as the standard stronger regimen for people with early-stage HER2-positive breast cancer. 186 participants received either the milder or standard treatment before surgery. The goal is to see if the gentler approach can still eliminate the cancer while causing fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
P.A. Hertsen Moscow Oncology Research Institute
Moscow, 125284, Russia
Conditions
Explore the condition pages connected to this study.